Esmolol formulation

Details for Australian Patent Application No. 2002309475 (hide)

Owner Baxter International Inc.

Inventors PEJAVER, Satish, K.; LIU, Jie; OWOO, George

Agent Peter Maxwell & Associates

Pub. Number AU-B-2002309475

PCT Number PCT/US02/00329

PCT Pub. Number WO2002/076446

Priority 10/016,260 30.10.01 US; 09/759,547 12.01.01 US

Filing date 2 January 2002

Wipo publication date 8 October 2002

Acceptance publication date 3 August 2006

International Classifications

A61K 31/215 (2006.01)

A61K 47/02 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Inorganic compounds

A61K 47/26 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Carbohydrates

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

19 December 2002 Complete Application Filed

  Priority application(s): 10/016,260 30.10.01 US; 09/759,547 12.01.01 US

27 March 2003 Application Open to Public Inspection

  Published as AU-B-2002309475

3 August 2006 Application Accepted

  Published as AU-B-2002309475

30 November 2006 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002309476-METHOD OF PREVENTING T CELLMEDIATED RESPONSES BY THE USE OF THE MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II ANALOG PROTEIN (MAP PROTEIN) FROM STAPHYLOCOCCUS AUREUS

2002309474-COORDINATION SYNTHESIS FOR SOFTWARE SYSTEMS